✨
AI Summary
- FDA approved a second once-weekly basal insulin, efsitora alfa-gobe (Onswik).
- Efsitora offers a fixed weekly regimen with high-concentration pen formulations.
- This doubles once-weekly basal insulin options for type 2 diabetes adults.